AstraZeneca slips on US diabetes news but Shire climbs on deal talk

Discussion in 'Market News' started by Lily, Oct 16, 2015.

  1. Lily

    Lily Forum Member

    Joined:
    Aug 29, 2015
    Messages:
    8,753
    Likes Received:
    3
    US regulators seek more data before approving AstraZeneca treatment

    AstraZeneca has slipped back in a rising market after a delay to the launch of a diabetes treatment.

    The US Food and Drug Administration declined to approve a combination of saxagliptin and dapagligiozin and said more clinical data was required. When AstraZeneca successfully defended itself against a $118bn takeover attempt by Pfizer, the company forecast the combination could produce peak revenues of £3bn.

    Continue reading...
     

Share This Page

free forex signals